Skip to main content
NVDA-2.25%AAPL+1.57%GOOGL-0.06%MSFT+0.03%AMZN+0.06%TSM-1.07%SPCX+2.86%AVGO-0.14%META-0.24%TSLA-0.42%SKHY-3.56%MU-4.74%BRK-B-0.27%LLY+0.22%JPM-0.67%AMD-3.20%WMT+0.17%V-0.02%XOM+0.42%ASMLa-1.66%JNJ-0.47%INTC-4.99%MA-0.34%0700.HK-1.94%ORCL-2.93%1398.HK+0.79%BAC-0.62%ABBV+0.39%CSCO-0.88%CVX-0.17%COST+0.13%LRCX-4.58%KO+1.03%CAT-1.61%AMAT-2.27%0005.HK-0.78%AP2d-1.55%UNH-0.51%DELL-3.43%HSBA.L-1.30%MS-0.69%PG-0.16%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.12%HD-1.18%GS-0.90%0939.HK+1.66%NZDJPY-2.59%AUDJPY-1.84%CHFJPY-1.57%NZDCAD-1.46%EURNZD+1.42%GBPNZD+1.37%USDJPY-1.32%NZDUSD-1.31%GBPJPY-1.24%EURJPY-1.21%CADJPY-1.14%NZDCHF-1.06%USDZAR+0.91%EURZAR+0.84%AUDNZD+0.78%GBPZAR+0.76%USDNOK+0.76%USDSEK+0.75%AUDCAD-0.73%EURNOK+0.69%EURSEK+0.68%AUDDKK-0.67%EURAUD+0.64%GBPAUD+0.59%CHFNOK+0.55%CHFSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%USDTHB+0.48%USDMXN+0.44%GBPTRY+0.41%CADCHF+0.41%NZDSGD-0.37%EURCHF+0.35%NOKJPY-0.33%GBPHKD+0.32%GBPCHF+0.32%USDPLN+0.31%GBPMXN-0.28%AUDCHF-0.28%USDCHF+0.26%EURPLN+0.24%SGDJPY+0.21%USDSGD+0.21%USDILS+0.16%NZDMXN-0.16%USDCAD-0.16%EURSGD+0.14%GBPCAD-0.11%PLNJPY+0.11%USDTRY+0.11%EURUSD+0.09%EURCZK-0.08%EURHKD-0.08%USDCNH+0.08%GBPUSD+0.08%EURCAD-0.07%USDDKK+0.07%GBPSGD+0.05%EURGBP+0.04%USDCOP-0.04%EURCNH+0.03%AUDNOK+0.02%USDHKD+0.01%EURDKK0.00%CHFSGD0.00%XPTUSD-5.44%UKOIL+4.82%XAGUSD-4.74%HG1-4.74%GAGUSD-4.72%USOIL+4.60%SUGAR+2.62%GAUUSD-1.00%XAUUSD-0.99%COTTON+0.71%COFFEE-0.61%XNGUSD+0.61%BTCUSD-1.69%ETHUSD-1.16%USDTUSD-0.03%XRPUSD-3.13%SOLUSD-2.14%TRXUSDT-0.03%ZECUSDT-7.21%DOGEUSD-3.27%XMRUSDT-1.52%LINKUSD-1.88%XLMUSD-2.42%BCHUSDT-10.66%LTCUSD-2.36%UNIUSD-3.05%TONUSD+24.88%HBARUSDT-2.57%SUIUSD-4.11%TAOUSDT-5.96%AAVEUSD-3.34%DOTUSDT-3.52%ICPUSDT-1.44%ONDOUSDT-3.87%WLDUSDT-3.39%ARBUSDT-0.46%ATOMUSDT-5.13%JUPUSDT-4.25%INJUSDT-5.65%STXUSDT-4.53%FETUSDT-4.15%TIAUSDT-2.18%PYTHUSDT-1.47%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-2.91%WIFUSDT-5.87%OPUSDT-4.00%POLUSDT-6.03%IOTAUSDT-4.48%AXSUSDT-2.90%FARTCOINUSDT-4.41%EOSUSDT-1.67%DYDXUSDT-3.58%ORDIUSDT-1.88%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.25%AAPL+1.57%GOOGL-0.06%MSFT+0.03%AMZN+0.06%TSM-1.07%SPCX+2.86%AVGO-0.14%META-0.24%TSLA-0.42%SKHY-3.56%MU-4.74%BRK-B-0.27%LLY+0.22%JPM-0.67%AMD-3.20%WMT+0.17%V-0.02%XOM+0.42%ASMLa-1.66%JNJ-0.47%INTC-4.99%MA-0.34%0700.HK-1.94%ORCL-2.93%1398.HK+0.79%BAC-0.62%ABBV+0.39%CSCO-0.88%CVX-0.17%COST+0.13%LRCX-4.58%KO+1.03%CAT-1.61%AMAT-2.27%0005.HK-0.78%AP2d-1.55%UNH-0.51%DELL-3.43%HSBA.L-1.30%MS-0.69%PG-0.16%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.12%HD-1.18%GS-0.90%0939.HK+1.66%NZDJPY-2.59%AUDJPY-1.84%CHFJPY-1.57%NZDCAD-1.46%EURNZD+1.42%GBPNZD+1.37%USDJPY-1.32%NZDUSD-1.31%GBPJPY-1.24%EURJPY-1.21%CADJPY-1.14%NZDCHF-1.06%USDZAR+0.91%EURZAR+0.84%AUDNZD+0.78%GBPZAR+0.76%USDNOK+0.76%USDSEK+0.75%AUDCAD-0.73%EURNOK+0.69%EURSEK+0.68%AUDDKK-0.67%EURAUD+0.64%GBPAUD+0.59%CHFNOK+0.55%CHFSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%USDTHB+0.48%USDMXN+0.44%GBPTRY+0.41%CADCHF+0.41%NZDSGD-0.37%EURCHF+0.35%NOKJPY-0.33%GBPHKD+0.32%GBPCHF+0.32%USDPLN+0.31%GBPMXN-0.28%AUDCHF-0.28%USDCHF+0.26%EURPLN+0.24%SGDJPY+0.21%USDSGD+0.21%USDILS+0.16%NZDMXN-0.16%USDCAD-0.16%EURSGD+0.14%GBPCAD-0.11%PLNJPY+0.11%USDTRY+0.11%EURUSD+0.09%EURCZK-0.08%EURHKD-0.08%USDCNH+0.08%GBPUSD+0.08%EURCAD-0.07%USDDKK+0.07%GBPSGD+0.05%EURGBP+0.04%USDCOP-0.04%EURCNH+0.03%AUDNOK+0.02%USDHKD+0.01%EURDKK0.00%CHFSGD0.00%XPTUSD-5.44%UKOIL+4.82%XAGUSD-4.74%HG1-4.74%GAGUSD-4.72%USOIL+4.60%SUGAR+2.62%GAUUSD-1.00%XAUUSD-0.99%COTTON+0.71%COFFEE-0.61%XNGUSD+0.61%BTCUSD-1.69%ETHUSD-1.16%USDTUSD-0.03%XRPUSD-3.13%SOLUSD-2.14%TRXUSDT-0.03%ZECUSDT-7.21%DOGEUSD-3.27%XMRUSDT-1.52%LINKUSD-1.88%XLMUSD-2.42%BCHUSDT-10.66%LTCUSD-2.36%UNIUSD-3.05%TONUSD+24.88%HBARUSDT-2.57%SUIUSD-4.11%TAOUSDT-5.96%AAVEUSD-3.34%DOTUSDT-3.52%ICPUSDT-1.44%ONDOUSDT-3.87%WLDUSDT-3.39%ARBUSDT-0.46%ATOMUSDT-5.13%JUPUSDT-4.25%INJUSDT-5.65%STXUSDT-4.53%FETUSDT-4.15%TIAUSDT-2.18%PYTHUSDT-1.47%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-2.91%WIFUSDT-5.87%OPUSDT-4.00%POLUSDT-6.03%IOTAUSDT-4.48%AXSUSDT-2.90%FARTCOINUSDT-4.41%EOSUSDT-1.67%DYDXUSDT-3.58%ORDIUSDT-1.88%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%
PT

Palvella Therapeutics, Inc. (PVLA)

NASDAQ • Healthcare

$151.34
-$0.93 (-0.6%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$147.26
Previous Close$151.34
Day Range$145.91 - $155
Avg. Volume (3M)189.3K
Market Cap$2.1B
52 Week Range
$53.3$161.38
Next EarningsIn 61 daysNov 10, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$61.6M
EPS (TTM)
-$4.83
ROA (TTM)
-24.34%
Current Ratio
21.18

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-18.5%Q1 2026-$1.08
-33.3%Q2 2026-$1.2
-29.9%Q3 2026-$1.52
Next

Nov 10

in 61 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -29.9%

Palvella Therapeutics’ preliminary results showed EPS trailing consensus in the second fiscal quarter of 2026, reported August 4, 2026, with EPS of -$1.52 trailing the -$1.17 estimate by -$0.35. The clinical-stage biotech, focused on inherited skin conditions including its QTORIN rapamycin gel program, posted a GAAP net loss of about $21.9 million, deeper than the roughly $9.5 million loss a year ago (net income YoY -130.9%), while operating income was about -$21.4 million. EPS was down -76.7% year over year from -$0.86. Cash generation was also negative, with operating cash flow of about -$12.8 million. For the next period, consensus calls for EPS of -$1.74 on revenue of $16,667.00.

View full earnings history

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops treatments for inherited skin conditions. In qualitative terms, it is a clinical-stage biopharmaceutical company, with its work centered on QTORIN 3.9% rapamycin anhydrous gel and related rapamycin programs rather than commercialized product sales.

Name
Palvella Therapeutics, Inc.
CEO
Wesley H. Kaupinen
Website
palvellatx.com
Industry
Healthcare
Employees
29

Today's Snapshot

AI-generated

The session opened with PVLA 1.9% lower at 148.43, while its sector was flat. Palvella Therapeutics named Dr. James R. Treat as its chief medical officer.

Trading Volume

Below 10d avg (168.3K)

40.9K

vs S&P 500 Today

Underperforming Market

-0.78%

Updated: September 10, 2026 at 14:41 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
PVLA reads as a neutral, mixed-stance setup with short-term moving averages slightly above the current price while medium- and long-term averages remain supportive, reflecting conflicting signals across timeframes. Momentum is mildly negative and oscillators hover near neutral, while MACD shows modest positive bias and ADX indicates little trend strength. Volume on balance is constructive and volatility is moderate, suggesting range-bound conditions. The pivot level sits marginally above the market, offering a nearby reference. Technical takeaway: Neutral — short-term weakness versus longer-term moving-average support with limited trend conviction.
All signals
  • EMA (5 indicators)$119.59 - $151.86
    Buy
  • RSI (14)49.47
    Neutral
  • Stochastic %K (14, 3, 3)68.79
    Neutral
  • MACD Level (12, 26)1.48
    Neutral

Peers & Related Assets

TYRATyra Biosciences, Inc.
$22.01-17.7%
SVRASavara Inc.
$5.42-2.0%
KURAKura Oncology, Inc.
$12.09-3.4%
ABUSArbutus Biopharma Corp
$5.17-0.2%
SPRYARS Pharmaceuticals, Inc.
$5.23-3.0%
EYPTEyePoint Pharmaceuticals, Inc.
$4.34-4.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.